Genelux Corporation (GNLX) Reports $10.3M Q3 Net Loss; Cash Runway Into 1Q27
Genelux (GNLX) reported a Q3 2026 net loss of $10.3M, or $0.23 per share, compared to $8.0M, or $0.21 per share, in Q3 2025. The company has $15.5M in cash and expects funding into 1Q27. Genelux is in late clinical-stage trials for ovarian and lung cancer, with key data expected in 2H26.
